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The ryanodine receptor (RyR) is the principal Ca#+-release





R) is primarily responsible for Ca#+ release
in non-excitable cells, including epithelia. RyR also is expressed
in a number of non-excitable cell types, but is thought to serve as
an auxiliary or alternative Ca#+-release pathway in those cells.
Here we use reverse transcription PCR to show that a polarized
epithelium, the pancreatic acinar cell, expresses the type 2, but
not the type 1 or 3, isoform of RyR. We furthermore use
immunochemistry to demonstrate that the type 2 RyR is dist-
ributed throughout the basolateral and, to a lesser extent, the




#+) regulates a wide range of cell functions
[1,2] and plays a particularly important role in controlling





#+ waves and other types of Ca
i
#+ grad-
ients, may be essential for the proper regulation of epithelial
secretion [4]. Since the effective range of diffusion of Ca#+ is
highly limited in cytosol [5], these spatial patterns of Ca
i
#+ signals
likely depend upon the subcellular distribution of Ca
i
#+-release
channels. The two major channels that regulate release of Ca#+









R is thought to
be primarily responsible for Ca
i
#+ signals in epithelia [1], since
increases in Ca
i
#+ originate at the site of this receptor [6–8] and
since InsP
$
R antagonists block Ca
i
#+ signalling in these cells
[9,10]. However, InsP
$
R is restricted to the extreme apex in
epithelial cells [6–8], which suggests that RyR may be expressed
in other regions of these cells and supports propagation of Ca
i
#+
waves to those regions. The goal of the present study was to
determine the expression and subcellular location of RyR in
pancreatic acinar cells. RyR was localized in acinar cells because
other features of Ca
i
#+ signalling have been characterized ex-
tensively in this model polarized epithelium [4,6,9–12].
MATERIALS AND METHODS
Reverse transcription (RT) and PCR amplification
Rat pancreatic acini were prepared as described in [6], and total
RNA was isolated by standard methods [13,14]. A 1 µg sample
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zone, where cytosolic Ca#+ signals originate in this cell type.
Since propagation of Ca#+ waves in acinar cells is sensitive to
ryanodine, caffeine and Ca#+, these findings suggest that Ca#+
waves in this cell type result from the co-ordinated release of
Ca#+, first from InsP
$
Rs in the trigger zone, then from RyRs
elsewhere in the cell. RyR may play a fundamental role in Ca#+




Key words: calcium, calcium-release channels, cyclic ADP-
ribose, inositol trisphosphate.
of RNA was used in 20 µl of cDNA-synthesis reaction mixture.
The reaction was carried out using an RNA PCR kit (Perkin




reverse transcriptase. Two control cDNA reactions were carried
out. In one, RNA, but no reverse transcriptase, was added (RNA
control), while in the other no RNA was added (DNA control).
PCR amplification was performed in a PTC-100 automated
thermocycler (MJ Research, Watertown, MA, U.S.A.) using 2 µl
of the first-strand cDNA reaction, 150 pmol of each degenerate
primer, 50 µM dNTPs, 2.5 units of AmpliTaq DNA polymerase
in 10 mM Tris}HCl, pH 8.3, containing 50 mM KCl and 2.5 mM
MgCl
#
in a total volumeof 100 µl. After a hot start (2 min at 94 °C),
the samples were subjected to 30 cycles of 45 s at 94 °C, 1 min at
50 °C and 1 min at 72 °C. This was followed by a final extension
at 72 °C for 10 min. The degenerate primers were designed to
amplify a 530 bp product from the 3« region of all three known
RyRs [15–17]. The forward primer was 5«-CA(C}T)(C}T)T-
(A}C}G}T)(C}T)T(A}C}G}T)GA(C}T)AT(A}C}T)GCIATG-
GG-3« and the reverse primer was A(A}G}T)(A}G)TA(A}G)-
TT(A}C}G}T)GCIA(A}G)(A}G)TT(A}G)TG(C}T)-TC-3«.The
resulting PCR product was analysed by agarose-gel electro-
phoresis.
Restriction-enzyme analysis of the RT-PCR product
The restriction enzymes SacI, BglII and EaeI were used to
determine which RyR isoforms were amplified [16,17]. SacI
only cuts type 1 RyR (RyR-1), into fragments of E 395 bp
and 135 bp, BglII cuts only type 2 RyR (RyR-2), into
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fragments of E 295 bp and 235 bp, whereas EaeI cuts RyR-3
only, into 350 bp and 180 bp fragments. Digestion products were
analysed on a 2%-agarose gel.
Cloning and sequencing of RT-PCR products
The PCR products were separated electrophoretically on a 1.5%-
agarose gel and revealed under UV light. A single band, of
predicted size, was cut out of the gel and purified using a DNA
purification kit (American Bioanalytical, Natick, MA, U.S.A.).
The purified DNA was cloned into a TA cloning vector (In-
Vitrogen, San Diego, CA, U.S.A.), according to the manufac-
turer’s instructions. DNA from 20 colonies was purified, and
subjected to restriction-enzyme analysis with EcoRI to identify
positive clones. The clone containing an insert of the expected size
was sequenced in both directions and aligned with previously
published RyR sequences to determine which isoform was
present.
Western-blot analysis
Immunoblotting was performed to demonstrate protein ex-
pression of RyR-2 in the acinar cells, to confirm lack of expression
of RyR-1 and RyR-3 in the acinar cells, and to confirm specificity
of immunochemical labelling for RyR-2 in pancreas. Immuno-
blotting of acinar-cell and cardiac lysates was performed using
mouse monoclonal antibody C3-33 directed against the canine
cardiac RyR-2 [18]. Immunoblotting of acinar-cell and dia-
phragmatic lysates was performed using mouse monoclonal
antibody XA7 B6, directed against the rabbit skeletal-muscle
RyR-1 [19], or using an affinity-purified polyclonal antibody
directed against a peptide sequence specific to RyR-3 [20].
Diaphragm was used as a positive control for both RyR-1 and
RyR-3, since that tissue contains both of these isoforms [21].
Acinar cells and cardiac and diaphragmatic lysates were diluted
in Laemmli reducing sample buffer [22], and boiled for 5 min.
The samples were then electrophoresed through a SDS}
polyacrylamide 4–20% gradient gel, electrophoretically trans-
ferred on to an Immobilon polyvinylidene membrane, and
incubated with anti-RyR antibody. Immunoreactive bands were
detected by incubation with protein A–horseradish peroxidase
conjugate followed by revelation with enhanced chemilumi-
nescence (ECL2, Amersham) reagents.
Confocal immunofluorescence histochemistry
To determine the subcellular distribution of RyR, sections of rat
pancreas were labelled with anti-RyR-2 antibody C3-33 [18].
Specimens were co-labelled with Texas Red–phalloidin, because
this stain facilitates identification of the apical and basolateral
poles of pancreatic acinar cells [23]. Negative controls for RyR
labelling were stained with secondary antibodies alone, along
with Texas Red–phalloidin. Sections of rat heart were fixed and
labelled with anti-RyR-2 antibodies as a positive control, since
the immunohistochemistry of RyR-2 in myocardium has been
well described [18]. Separate sections of rat pancreas were labelled
with a mouse monoclonal antibody directed against the N-
terminal end of the human type 3 InsP
$
R (Transduction Labora-
tories, Lexington, KY, U.S.A.), to compare the distribution of
InsP
$
R-3 with that of RyR-2.
Immunochemistry was performed on 4-µm-thick frozen
sections of rat pancreas. For RyR-2 staining, tissue was fixed by
perfusion with 2% (w}v) paraformaldehyde in 0.075 M sodium
phosphate, pH 7.3, cryopreserved overnight in 15% (w}v) su-
crose, and frozen in isopentane}liquid nitrogen. After quenching
with 50 mM NH
%
Cl and 3% (v}v) goat serum in PBS, the
sections were labelled with a 1:5 dilution of anti-RyR-2 antibody
overnight, then washed and incubated with Alexa 488 (a fluores-
cent dye)-conjugated anti-mouse secondary antibodies (Mol-
ecular Probes, Eugene, OR, U.S.A.), along with Texas Red-
conjugated phalloidin [23,24]. Negative controls were stained
with Alexa 488-conjugated anti-mouse secondary antibodies
alone, along with Texas Red-conjugated phalloidin. Perfusion
fixation plus all washes and incubations included pepstatin
(2 µM), PMSF (0.2 mM),and benzamidine (0.5 mM) to inhibit
proteolysis [6]. Specimens were examined with a Bio-Rad MRC-
600 confocal microscope equipped with a krypton}argon mixed-
gas laser [6]. To ensure specificity of RyR-2 staining, images were
obtained using confocal machine settings (i.e., aperture, gain and
black level) at which no fluorescence was detectable in negative
control samples labelled with secondary antibody alone. Double-
labelled specimens were serially excited at 488 nm and observed
at " 515 nm to detect Alexa 488, then excited at 568 nm and
observed at " 585 nm to detect Texas Red. This approach
eliminated bleed-through of Alexa 488 fluorescence into the
Texas Red channel [6].
In order to localize the type 3 InsP
$
R [6], pancreas was
cryopreserved in sucrose, then fixed in ice-cold acetone for
10 min, blocked with 1% BSA, labelled with a 1:100 dilution of
the mouse monoclonal anti-InsP
$
R-3 antibody, and counter-
stained with Alexa 488-conjugated anti-mouse secondary anti-
bodies. Labelled tissue was examined by confocal fluorescence
microscopy as described above.
Immunochemistry was performed on 8-µm-thick sections of
cardiac tissue, which were frozen unfixed, then fixed with ice-cold
methanol for 10 min immediately prior to staining. The sections
were blocked with PBS solution containing 1% BSA, stained
with the anti-RyR-2 antibody, counterstained with FITC-goat
anti-mouse secondary antibody, and examined by confocal
fluorescence microscopy as described above.
RESULTS
Expression of RyR in pancreatic acinar cells
RT-PCR was used to amplify RyR cDNA from rat pancreatic-
acinar-cell RNA using degenerate primers from two sequences
common to each of the three known RyR isoforms [15,16]. A
single 530 bp PCR product was identified (Figure 1), which was
then digested using the restriction enzymes SacI, BglII and EaeI
to look for RyR-1, RyR-2 and RyR-3 respectively [16]. BglII
digestion resulted in two fragments, whereas SacI and EaeI had
Figure 1 RT-PCR detection of RyR in pancreatic acinar cells
Using isoform-specific primers, a single 530 bp product was identified in pancreatic acinar
mRNA, but not in RNA- or DNA-negative controls.
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Figure 2 Restriction-enzyme analysis of RyR RT-PCR product in pancreatic
acinar cells
The 530 bp PCR product shown in Figure 1 was digested using Sac I, Bgl II, and Eae I to detect
RyR-1, RyR-2 and RyR-3 respectively. Bgl II digestion revealed two fragments, whereas Sac I
and Eae I had no effect.
no effect on the PCR product (Figure 2). The original 530 bp
PCR product was then sequenced and found to be 94% identical
with RyR-2 of Mus musculus (house mouse) (Figure 3) and 88%
identical with rabbit RyR-2. These sequencing data demonstrate
that the small amount of PCR product remaining after BglII
digestion (Figure 2) was due to incomplete digestion rather than
to RyR-1 or RyR-3 that was present as well. Thus these findings
show that pancreatic acinar cells express the RyR-2, but not
RyR-1 or RyR-3.
Detection of the RyR-2 in pancreas by Western blotting.
Immunoblot analysis was used to test for the presence of RyR
isoforms in rat pancreatic lysates (Figure 4). Blots probed with
anti-RyR-2 antibody C3-33 showed a single band of immuno-
reactivity with an apparent molecular mass of E 565 kDa (Figure
4A). A single band of immunoreactivity with the same molecular
mass was identified in lysates from rat heart (Figure 4A), which
Figure 3 The RT-PCR product of pancreatic acinar cells shows high
sequence similarity to RyR-2
The sequence of the RT-PCR product (Panc) was determined and compared with the sequence
of the corresponding portion of RyR-2 message of M. musculus (M musc). The two sequences
are 94% identical at the nucleotide level.
Figure 4 Pancreatic acinar cells express RyR-2, but not RyR-1 or RyR-3
protein by immunoblot
(A) Western analysis using RyR-2 monoclonal antibody C3-33 identifies a single E 565 kDa
band in lysates from both heart and pancreas. Expression in heart is intense, as expected.
(B) Western analysis using anti-RyR-1 monoclonal antibody XA7 B6 identifies a single band in
lysate from diaphragm (which expresses both RyR-1 and RyR-3), but not from pancreatic lysate.
(C) Similarly, Western analysis using an affinity-purified polyclonal antibody directed against
RyR-3 identifies a single band in lysate from diaphragm but not from pancreas.
is known to heavily express RyR-2. In contrast, blots probed
with antibody directed against RyR-1 (Figure 4B) or RyR-3
(Figure 4C) showed no immunoreactivity. These results dem-
onstrate that the RyR-2, but not RyR-1 or RyR-3, is expressed
in rat pancreas, and confirm the specificity of antibody C3-33 for
labelling RyR-2.
Subcellular localization of the RyR-2 by confocal microscopy.
To localize RyR within pancreatic acinar cells, slices of rat
pancreas were double-labelled with Texas Red-conjugated
phalloidin and with anti-RyR-2 antibody C3-33, and then
detected with fluorescently labelled secondary antibodies (Figures
5A–5C). The extreme apex of acinar cells, where the trigger zone
is located [6–8], was identified by intense phalloidin labelling of
actin along the apical membrane (Figure 5A), as previously
reported [23]. RyR-2 staining labelled acinar cells much more
diffusely (Figure 5B). Double-label images revealed that RyR-2
staining was largely in the basolateral region of the acinar cells
and was specifically excluded from the extreme apical region of
these cells (Figure 5C). Slices of rat heart stained with anti-RyR-
2 antibody (Figure 5D) revealed an intracellular pattern that
corresponds to the sarcoplasmic reticulum, along which RyR-2
is known to be distributed in myocytes [18]. To compare the
distribution of RyR-2 and InsP
$
R more directly, separate slices
of rat pancreas were labelled with an antibody directed against
type 3 InsP
$
R (Figure 5E). In contrast with RyR-2 staining, that
of InsP
$
R was localized to the extreme apex, in a pattern very
similar to that of Texas Red–phalloidin and consistent with
previous reports [6–8]. These results confirm that pancreatic
acinar cells express RyR-2 and demonstrate that the receptor is
distributed throughout the basolateral, and to a lesser extent the





Here we describe the expression and subcellular location of RyR-
2 in pancreatic acinar cells. The central role of RyR in Ca
i
#+
signalling in muscle and nerve cells is well known [15,25,26].
More recently, RyR expression has been described in a number
of non-excitable cell types as well [15,16]. Expression of the
various RyR isoforms has been described in several types of
epithelia in particular, including RyR-2 in kidney cells and cell
lines [27], RyR-2 and RyR-3 in the T84 colonic cell line [17], and
RyR-1 and RyR-3 in parotid acinar cells [28,29]. Studies that
show [$H]ryanodine binding to microsomes and effects of
ryanodine on Ca
i
#+ signalling in these and other epithelia suggest
308 M. F. Leite and others
Figure 5 Comparison of the subcellular localization of the type 2 RyR and the type 3 InsP3R in pancreas, as determined by confocal immunofluorescence
microscopy
(A) Texas Red–phalloidin labelling of pancreas identifies the plasma membranes of the acinar cells. Labelling is most intense along the apical membranes, the site of the trigger zone where InsP3R
is most concentrated. (B) Distribution of RyR-2, labelled with anti-RyR-2 antibody C3-33. (C) Superimposed images (A) and (B), demonstrating the polarized distribution of RyR-2 in acinar cells.
Receptor labelling is diffusely distributed, but is most concentrated in the basolateral region and is excluded from the trigger zone. (D) Staining of cardiac tissue using anti-RyR-2 antibody
C3-33. Labelling of the sarcoplasmic reticulum by RyR antibody is evident. (E) Distribution of the type 3 InsP3R in a separate section of pancreas, labelled with a monoclonal antibody directed against
the N-terminal region of the human InsP3R-3. In contrast with RyR-2, InsP3R-3 is concentrated in the trigger zone, similar to the distribution of Texas Red–phalloidin.
a functional role for epithelial RyRs [17,27–29]. However, the
precise role of RyR in epithelial Ca
i
#+ signalling has not been
completely defined, in part because the subcellular location of
this receptor in such cells was unknown. Recently, fluorescently
labelled ryanodine was used to observe that ryanodine binding
occurs diffusely in the cytosol of parotid acinar cells [29].
However, the polarity of the distribution of the fluorescent tag
was not examined. In addition, ryanodine-binding sites do not
always reflect the location of RyR itself, as evidenced by the fact
that hepatocyte microsomes contain ryanodine-binding sites
[30,31], yet hepatocytes do not express RyR [15]. In another
recent study, immunochemistry was used to examine RyR
expression in pancreatic acini, but no labelling was detected [8].
This negative finding could in part reflect the fact that anti-RyR
antibodies used in that study were not specific for RyR-2 [8].
Here, molecular techniques were used to demonstrate the pres-
ence of RyR-2 message in pancreatic acinar cells, and immuno-
blotting was used to demonstrate both RyR-2 protein expression
in the acinar cells and the specificity of the particular anti-RyR-
2 antibody. Immunochemistry was then used and it showed that
RyR-2 is expressed in a polarized fashion in pancreatic acinar
cells : it is diffusely distributed across the basolateral region and
excluded from the extreme apex.
The current findings have important implications for the
mechanism of Ca
i
#+ wave propagation in pancreatic acinar cells.
Agonist-induced Ca
i
#+ signals in these cells begin in a highly
localized region in the apex which has been called the ‘ trigger
zone’ [10]. Increases in Ca
i
#+ then may either remain as localized
apical Ca
i
#+ pulses, or else spread as a non-diminishing Ca
i
#+
wave across the remainder of the cell [9–12]. Initial increases in
Ca
i




R is localized to
the region of the trigger zone [6–8], so this distribution of the
receptor likely accounts for the polarized fashion in which Ca
i
#+
signals are initiated in this cell type. Ca
i
#+ waves then spread
309Ryanodine receptors in pancreas
from the trigger zone in a manner that is sensitive to ryanodine
and caffeine, both of which are known to modulate RyR activity
[32]. In addition, direct microinjection of Ca#+ into pancreatic
acinar cells causes Ca#+-induced Ca#+ release, which originates
in a region distinct from the trigger zone [10]. Finally, increases in
Ca
i
#+ in pancreatic acinar cells can be initiated by the RyR agonist
cyclic ADP-ribose (cADPR), and these cADPR-induced Ca
i
#+
signals are sensitive to ryanodine [33]. Together, these findings
suggest that the spread of Ca
i
#+ waves away from the trigger zone
is mediated by Ca#+ release from RyR. The present study provides
direct support for this hypothesis by demonstrating that RyR
is present in pancreatic acinar cells, and that this receptor is
distributed in regions of the acinar cell that would account for
the pattern of Ca
i
#+ waves that is experimentally observed. In
addition, RyR present in pancreatic acinar cells is the type 2
isoform, and this isoform is thought to be sensitive to cADPR
[34,35], which also is consistent with previous observations in
acinar cells [33].
These findings may have more general implications for cellular
Ca
i
#+ signalling mechanisms as well. RyR is of primary im-
portance for Ca#+ release in excitable cells [26,36,37], while
InsP
$
R had been thought to govern Ca#+ release in non-excitable
cells [1]. However, InsP
$
R also is expressed in excitable cells
[38,39], while RyR also is expressed in non-excitable cells [15,16].
Until now, an independent and somewhat limited role had been
suggested for each of these receptors in cells in which they are not
thought to be of primary importance for Ca
i
#+ signalling. For
example, in cardiac myocytes, RyR is found along sarcoplasmic
reticulum throughout the cell, and Ca
i
#+ sparks in the cytosol
trigger Ca#+-induced Ca#+ release via RyR, inducing excitation–
contraction coupling [37]. In contrast, InsP
$
R is concentrated at
the intercalated discs [38] and is thought to represent a back-up
mechanism for initiating Ca
i
#+ signals in disease states in which
RyR function may be impaired [40]. In sea-urchin eggs, both
InsP
$
R and RyR are distributed throughout the cell, and
either InsP
$
or cADPR can induce transcellular Ca
i
#+ waves [41].
In those cells, it is postulated that the two receptors regulate
redundant signalling pathways [41]. In lacrimal acinar cells, both
acetylcholine and phenylephrine increase Ca
i
#+, but stimulation





whileα-adrenergic stimulation instead increases Ca
i
#+ via cADPR
and RyR [42,43]. These disparate examples each demonstrate the
assumption that InsP
$
R and RyR are activated by independent,
albeit alternative, signalling pathways. However, in light of
previous findings in acinar cells [10,32,33], the present study
provides evidence that InsP
$
R-mediated and RyR-mediated Ca#+
release instead can be activated in an integrated, co-ordinated,
and sequential fashion. Further work will be needed to dem-
onstrate more directly that RyR and InsP
$
R interact in order to
organize the subcellular pattern of Ca
i
#+ signalling in pancreatic
acini and in other types of cells.
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